GlassScriptPhysician profile
Amer K Syed
NPI 1023214418
$140,961.30
in general payments reported to CMS, 2019-2025
59 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $24K · 2021: $50K · 2022: $16K · 2023: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Food and Beverage: $2,587 · Travel and Lodging: $2,538 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,011.00 |
| Food and Beverage | $2,586.62 |
| Travel and Lodging | $2,538.43 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $46,779.67 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $28,285.20 | 2019-2023 | Repatha, Otezla, Tezspire |
| Abbvie INC. | $27,214.14 | 2019-2023 | Linzess, Vraylar, Creon |
| Allergan, INC. | $8,912.84 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $8,602.48 | 2019-2023 | Trulance, Xifaxan, Cycloset |
| Biohaven Pharmaceuticals, INC. | $7,604.86 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $1,228.90 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,140.02 | 2021-2023 | |
| Alcresta Therapeutics, INC. | $1,000.00 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $997.85 | 2019-2023 | Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $949.90 | 2019-2023 | |
| Glaxosmithkline, LLC. | $775.49 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Horizon Therapeutics Plc | $498.84 | 2019-2022 | |
| Medtronic, INC. | $490.83 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $449.64 | 2020-2023 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amer Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.